Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2020 Jun 5;20(7):408. doi: 10.1038/s41577-020-0362-x

SARS-CoV-2 cross-reactivity in healthy donors

Verena van der Heide 1,
PMCID: PMC7274045  PMID: 32504061

In this preprint by Ng et al., binding IgG antibodies to conserved epitopes from SARS-CoV-2 S and N proteins were detected by flow cytometry and ELISA in approximately 10% of healthy individuals with a recent history of infection by human endemic coronaviruses (HCoVs). Of note, sera from the same donors were found to have SARS-CoV-2 neutralization activity comparable to that of samples from seropositive patients with COVID-19, which suggests that cross-neutralizing antibodies developed in response to previous HCoV exposure might interfere with SARS-CoV-2 entry into target cells. Further studies are needed to assess the potentially protective role of pre-existing cross-reactive antibodies in healthy individuals in the context of COVID-19 immunopathogenesis.

Competing interests

The author declares no competing interests.

References

Original article

  1. Ng K, et al. Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans. bioRxiv. 2020 doi: 10.1101/2020.05.14.095414. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Nature Reviews. Immunology are provided here courtesy of Nature Publishing Group

RESOURCES